Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

  • STATUS
    Not Recruiting
  • participants needed
    1850
  • sponsor
    Akebia Therapeutics
Updated on 4 August 2021
Investigator
Akebia Therapeutics
Primary Contact
Research Site (0.0 mi away) Contact
+398 other location
maintenance treatment
dialysis
renal disease
darbepoetin alfa
vadadustat

Summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in subjects with NDD-CKD

Description

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with NDD-CKD

Details
Condition Anemia, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease, Non-dialysis-dependent Chronic Kidney Disease
Treatment darbepoetin alfa, vadadustat
Clinical Study IdentifierNCT02680574
SponsorAkebia Therapeutics
Last Modified on4 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note